Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improve survival in patients with non-metastatic malignancy and venous thromboembolism (VTE) - Lee,A.; Julian,J.A.; Levine,M.N. (J Thromb Haemost, 2003)